Clinical Experience With Desvenlafaxine in Treatment of Patients With Fibromyalgia Syndrome (Q39800410)

14 September 2017

Clinical Experience With Desvenlafaxine in Treatment of Patients With Fibromyalgia Syndrome (English)

1 reference

14 September 2017

0 references

Rob Allen

1

1 reference

PubMed ID

27139158

14 September 2017

Uma Sharma

series ordinal

2

1 reference

PubMed ID

27139158

14 September 2017

Suna Barlas

series ordinal

3

1 reference

14 September 2017

3 May 2016

1 reference

Clinical pharmacology in drug development

14 September 2017

1 reference

14 September 2017

6

1 reference

14 September 2017

224-233

1 reference

14 September 2017

3

1 reference

The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes

14 September 2017

1 reference

The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity

21 January 2018

1 reference

An internet survey of 2,596 people with fibromyalgia

21 January 2018

1 reference

Fibromyalgia: presentation and management with a focus on pharmacological treatment

21 January 2018

1 reference

Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia

21 January 2018

1 reference

Clinical and economic characteristics of patients with fibromyalgia syndrome.

21 January 2018

1 reference

Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

Treatment of fibromyalgia with antidepressants: a meta-analysis.

21 January 2018

1 reference

Pathophysiology of fibromyalgia

21 January 2018

1 reference

Venlafaxine Treatment of Fibromyalgia

21 January 2018

1 reference

An open clinical trial of venlafaxine treatment of fibromyalgia.

21 January 2018

1 reference

Milnacipran for treatment of fibromyalgia

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder

21 January 2018

1 reference

Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor

21 January 2018

1 reference

Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: making clinical trial data more understandable

21 January 2018

1 reference

Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder

21 January 2018

1 reference

Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial

21 January 2018

1 reference

Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study

21 January 2018

1 reference

Evaluation of efficacy of the perioperative administration of Venlafaxine or gabapentin on acute and chronic postmastectomy pain

21 January 2018

1 reference

Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial

21 January 2018

1 reference

Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial

21 January 2018

1 reference

Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia

21 January 2018

1 reference

Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.

21 January 2018

1 reference

Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder

21 January 2018

1 reference

Systematic review: Placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy-magnitude and patient-related predictors

21 January 2018

1 reference

Methodological issues in clinical trials of opioids for chronic pain

21 January 2018

1 reference

The impact of selective publication on clinical research in pain

21 January 2018

1 reference

The evidence for pharmacological treatment of neuropathic pain

21 January 2018

1 reference

Interpreting effect sizes and clinical relevance of pharmacological interventions for fibromyalgia

21 January 2018

1 reference

A comparison of the clinical features of fibromyalgia syndrome in different settings.

21 January 2018

1 reference

A meta-analysis of factors impacting detection of antidepressant efficacy in clinical trials: the importance of academic sites

21 January 2018

1 reference

Meta-analysis of the placebo response in antidepressant trials

21 January 2018

1 reference

Characteristics and healthcare costs of patients with fibromyalgia syndrome

21 January 2018

1 reference

An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder

21 January 2018

1 reference

7 January 2021

A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.

1 reference

7 January 2021

A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder.

1 reference

7 January 2021

Clinical trial outcome in neuropathic pain: Relationship to study characteristics

1 reference

7 January 2021

Identifiers

DOI

10.1002/CPDD.271

1 reference

14 September 2017

1 reference

PubMed ID

27139158